Prediabetes Screening Test Completed Within One Hour

This "two-in-one" test can identify individuals with impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT).

CeaProve, a product of Ceapro (Edmonton, AB, Canada), consists of six highly calibrated wafers containing 50 g of glycemic carbohydrate, fat, and protein. Once consumed the glycemic carbohydrate causes a measurable rise in blood glucose that can be determined with a glucose meter. The level of this rise in blood glucose following an oral glucose challenge is indicative of a person's diabetic status.

Ceapro signed a research, license, and supply agreement for CeaProve with IR2Dx Inc. (San Francisco, CA, USA). The objective of the partnership is to use planned clinical studies to demonstrate a number of advantages in side effect profile, detection of true positives, shorter time to completion, and improved palatability of the CeaProve meal.

Ceapro and IR2Dx will jointly cover the development cost. Ceapro will remain responsible for the manufacturing of the product and will receive royalties on net sales in addition to regulatory milestones. IR2Dx will have worldwide marketing rights for the hospital, clinic, and physician market, exclusive except in Canada, where Ceapro has retained co-promotion rights.

IR2Dx specializes in the development of clinical assays for diagnostic uses for the evaluation and treatment of metabolic syndrome, cardiovascular inflammation, and insulin resistance.

Related Links:
Ceapro